On September 10, 2026, Cosciens Biopharma Inc. revealed its acquisition of Nualtis Corp., a specialty pharmaceutical technology company based in Montreal. Nualtis specializes in oral thin-film drug delivery technologies for human and animal health. Cosciens, traded as TSX: CSCI and OTCQB: CSCIF, completed the initial part of a non-brokered private placement of unsecured convertible debentures. This move signifies Cosciens' expansion into innovative drug delivery methods, tapping into Nualtis' expertise in the field.